Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Hims & Hers Health Inc (NYSE: HIMS) closed at $49.41 up 6.76% from its previous closing price of $46.28. In other words, the price has increased by $6.76 from its previous closing price. On the day, 83.19 million shares were traded. HIMS stock price reached its highest trading level at $51.97 during the session, while it also had its lowest trading level at $46.4.
Ratios:
For a deeper understanding of Hims & Hers Health Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 34.28 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 47.01. For the most recent quarter (mrq), Quick Ratio is recorded 1.32 and its Current Ratio is at 1.59. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.11.
On June 04, 2025, Needham reiterated its Buy rating and also lowered its target price recommendation from $61 to $65.
TD Cowen Downgraded its Buy to Hold on April 29, 2025, while the target price for the stock was maintained at $30.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 23 ’25 when Okupe Oluyemi sold 23,107 shares for $47.25 per share. The transaction valued at 1,091,766 led to the insider holds 63,222 shares of the business.
Oluyemi Okupe bought 69,431 shares of HIMS for $2,914,713 on Jun 23 ’25. On Jun 17 ’25, another insider, Chi Michael, who serves as the Chief Commercial Officer of the company, sold 17,102 shares for $59.75 each. As a result, the insider received 1,021,844 and left with 278,654 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HIMS now has a Market Capitalization of 11059538944 and an Enterprise Value of 10800228352. As of this moment, Hims’s Price-to-Earnings (P/E) ratio for their current fiscal year is 71.92, and their Forward P/E ratio for the next fiscal year is 50.98. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.08. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.20 while its Price-to-Book (P/B) ratio in mrq is 20.11. Its current Enterprise Value per Revenue stands at 6.053 whereas that against EBITDA is 78.446.
Stock Price History:
The Beta on a monthly basis for HIMS is 2.04, which has changed by 1.3067226 over the last 52 weeks, in comparison to a change of 0.12748289 over the same period for the S&P500. Over the past 52 weeks, HIMS has reached a high of $72.98, while it has fallen to a 52-week low of $13.47. The 50-Day Moving Average of the stock is 1.21%, while the 200-Day Moving Average is calculated to be 44.99%.
Shares Statistics:
For the past three months, HIMS has traded an average of 44.10M shares per day and 63963830 over the past ten days. A total of 215.21M shares are outstanding, with a floating share count of 190.67M. Insiders hold about 14.81% of the company’s shares, while institutions hold 70.31% stake in the company. Shares short for HIMS as of 1749772800 were 61690896 with a Short Ratio of 1.40, compared to 1747267200 on 62338753. Therefore, it implies a Short% of Shares Outstanding of 61690896 and a Short% of Float of 34.23.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current rating of Hims & Hers Health Inc (HIMS) reflects the combined expertise of 4.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $0.26, with high estimates of $0.29 and low estimates of $0.22.
Analysts are recommending an EPS of between $1.16 and $0.87 for the fiscal current year, implying an average EPS of $1.04. EPS for the following year is $1.38, with 5.0 analysts recommending between $1.82 and $1.08.
Revenue Estimates
A total of 9 analysts believe the company’s revenue will be $550.06M this quarter.It ranges from a high estimate of $563.59M to a low estimate of $540.01M. As of the current estimate, Hims & Hers Health Inc’s year-ago sales were $315.65MFor the next quarter, 9 analysts are estimating revenue of $587.04M. There is a high estimate of $611.9M for the next quarter, whereas the lowest estimate is $549.7M.
A total of 14 analysts have provided revenue estimates for HIMS’s current fiscal year. The highest revenue estimate was $2.39B, while the lowest revenue estimate was $2.3B, resulting in an average revenue estimate of $2.35B. In the same quarter a year ago, actual revenue was $1.48BBased on 13 analysts’ estimates, the company’s revenue will be $2.82B in the next fiscal year. The high estimate is $3.02B and the low estimate is $2.55B.
